Selank Spray
Anxiolytic Research Peptide · Nasal Spray
Size: 5mg

Selank is a synthetic analog of the immunopeptide tuftsin, studied for anxiolytic and neuromodulatory signaling in research settings. Supplied here as a 5mg metered-dose nasal spray, pre-mixed and ready to use without reconstitution.
Selank (Tuftsin Analog)
Synthetic heptapeptide analog of the endogenous immunopeptide tuftsin
Developed within Russian neuropeptide research
Studied for anxiolytic and neuromodulatory effects
Investigated for GABAergic and BDNF-related signaling
Referenced in stress and cognition research models
Research Use Notes
Supplied pre-mixed in a metered-dose pump
No reconstitution required — do not add Research Water
Prime the pump before first use
Keep the bottle upright and capped between uses
Storage
Store refrigerated at 2 to 8°C, protected from light
Do not freeze
Freezing can split the solution and damage the pump
Handling
Handle the bottle sealed — do not dilute or decant
For laboratory research use only
Wipe the nozzle and re-cap after each use
Certificate of Analysis
Independently 8x Tested by Kovera Labs and/or ILS Labs
(Click here to learn about 8x testing)
All certificates are issued by independent ISO-accredited laboratories. Lot-specific documents are made available to qualified research professionals on request.
Frequently Bought Together
Commonly paired to support consistent, reliable experimentation.
Compound Information
Technical specifications
What Is Selank Spray?
Tuftsin analog · Thr-Lys-Pro-Arg-Pro-Gly-Pro
- Type
- Synthetic peptide (tuftsin analog)
- CAS Number
- 129954-34-3
- Molecular Weight
- 751.9 g/mol
- Amino Acids
- 7
Stability Information
2-8°C
12+ months
2-8°C
~30 days
Sources & References
Peer-reviewed research
Products are intended solely for laboratory and scientific research purposes. Not intended for human consumption, veterinary use, diagnosis, treatment, cure, or prevention of disease.


All the research compounds you need, with the confidence that every batch is 8× tested before it ships.
Subscribe to our Newsletter
Subscribe to our newsletter to get daily insights, news, updates.
















